The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | MRD evaluation: how, when and for which goal?
Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses the importance of using measurable residual disease (MRD) to guide therapy in multiple myeloma, and further explains how monitoring disease progression with MRD is the best way to ensure that patients are provided with the best treatment approach. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
